5th Floor, Rajapushpa Summit
Nanakramguda Rd, Financial District, Gachibowli
Hyderabad, Telangana - 500008
The Nasopharyngeal Cancer Market is segmented By Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, and Others), By End user and Geography.
2018 - 2026
Fastest Growing Market:
The Nasopharyngeal Cancer market is expected to witness a steady CAGR of 2.7% during the forecast period. Certain factors that are driving the market growth include a moderate rise in the burden of the disease and growing awareness towards diagnosis and treatment. According to the International Agency for Research on Cancer (IARC) 2018 report, estimates that there were about 129,000 new cases of nasopharyngeal cancer in 2018. Moreover, it is estimated that about 50,455 new cases of nasopharyngeal cancer will occur from 2018 to 2040.
There is a growing awareness of the diagnosis and treatment of nasopharyngeal cancer (NPC). Traditionally the public perception regarding nasopharyngeal cancer was very weak due to lack of government initiatives and low incidence rate of the disease. To increase community awareness for ethnicities, which are predisposed to nasopharyngeal cancer, various primary healthcare centers have started awareness campaigns to increase the awareness of nasopharyngeal cancer (NPC). Consequently, greater adoption of nasopharyngeal cancer diagnosis and treatment is being witnessed, which is driving the growth of the global nasopharyngeal cancer market.
As per the scope of the report, nasopharyngeal cancer is a disease in which malignant cancer cells form in the tissues of the nasopharynx (the upper part of the throat behind the nose). Among many factors, ethnic background along with being exposed to the Epstein-Barr virus can affect the risk of nasopharyngeal cancer. The nasopharyngeal cancer market is segmented by therapy, end-user and geography.
|By End user|
|Hospitals and Clinics|
|Ambulatory Surgery Centers|
|Other Other End users|
Report scope can be customized per your requirements. Click here.
Radiation therapy forms the primary modality of treatment in nasopharyngeal cancer. It is closely followed by chemotherapy in terms of both market share and use-case in patients. Newer and advanced modalities of nasopharyngeal cancer treatment include a combination of both radiotherapy and chemotherapy techniques. These treatment modalities are still in early clinical phases and will make a commercial appearance late during the end of the forecast period or maybe even after that. Furthermore, according to the American Cancer Society, nasopharyngeal cancer is much more common in certain parts of South Asia, the Middle East, and North Africa. In some parts of China, there are as many as 21 cases per 100,000 people each year. Thus, owing to the above factors the segment is expected to show growth in the near future.
To understand key trends, Download Sample Report
In Asia pacific, nasopharyngeal cancer is one of the most common cancers in the head and neck areas. Men are two to three times more likely to develop it than women. The peak age of incidence is between 50 and 60 years. Nasopharyngeal cancer is generally more common in Southeast Asia. The five countries with the highest incidence of nasopharyngeal cancer in the world were China, Indonesia, Vietnam, India and Malaysia, respectively. Furthermore, according to the World Cancer Research Fund International, in Brunei, the nasopharyngeal cancer rate was 9.9 (per 100,000 population) the highest rate, followed by the Maldives 6.7 and Indonesia 6.6 in 2018 respectively. Thus, a high incidence of nasopharyngeal cancer in Southeast Asia the market is expected to grow over the forecast period.
To understand geography trends, Download Sample Report.
The global nasopharyngeal cancer market is highly competitive and consists of a few major players. Companies like Biocon, Bristol Myers Squibb, Cyclacel Pharmaceuticals, F. Hoffman La-Roche, Merck & Co., Novartis, Pfizer, among others, hold the substantial market share in the Nasopharyngeal Cancer market.
1.1 Study Assumptions
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of the Cancer Disease
4.2.2 Growing Awareness Towards Diagnosis and Treatment
4.3 Market Restraints
4.3.1 High Cost of the Treatment
4.3.2 Side Effects Associated with the Disease
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Therapy
5.1.3 Radiation Therapy
5.2 By End user
5.2.1 Hospitals and Clinics
5.2.2 Ambulatory Surgery Centers
5.2.3 Other Other End users
5.3.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle-East and Africa
5.3.5 South America
126.96.36.199 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Biocon Limited
6.1.2 Bristol Myers Squibb
6.1.3 Cyclacel Pharmaceuticals
6.1.4 F. Hoffman La-Roche Ltd
6.1.5 Merck & Co., Inc.
6.1.6 Novartis AG
6.1.7 Pfizer, Inc.
6.1.8 GlaxoSmithKline Plc
6.1.10 Theravectys SA
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments